EP1539153A4
Therapeutic treatment for the metabolic syndrome and type 2 diabetes
Abstract
This record has no abstract on file.
Term
Term ended
Projected expiry passed 28 July 2023, 3.2 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both ways
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| WO9741873A1 | Cites | World Intellectual Property Organization (WIPO) | X | Search report | 1-20 |
| WO9741873A | Cites | World Intellectual Property Organization (WIPO) | – | – | – |
| DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; February 2002 (2002-02-01), PIJL H ET AL: "Modulation of monoaminergic neural circuits: Potential for the treatment of type 2 diabetes mellitus", XP002453157, Database accession no. EMB-2003278651 | Non-patent | – | – | Search report | – |
| CINCOTTA A H ET AL: "Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes", EXPERT OPINION ON INVESTIGATIONAL DRUGS 1999 UNITED KINGDOM, vol. 8, no. 10, 1999, pages 1683 - 1707, XP002453155, ISSN: 1354-3784 | Non-patent | – | – | Search report | – |
50 members in 14 offices
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 399180P | United States of America | – | |
| 39918002 | United States of America | P | |
| 627014 | United States of America | – | |
| 62701403 | United States of America | A | |
| 0323662 | United States of America | W |
Members50
| Document | Office | Kind | |
|---|---|---|---|
| WO2004010946A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2003252182A1 | Australia | A1 | |
| AU2003252182A8 | Australia | A8 | |
| US2004077679A1 | United States of America | A1 | |
| WO2004010946A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US2004220190A1 | United States of America | A1 | |
| US2005054652A1 | United States of America | A1 | |
| US2005054734A1 | United States of America | A1 | |
| EP1539153A2 | European Patent Office (EPO) | A2 | |
| CN1678313A | China | A | |
| US2007005962A1 | United States of America | A1 | |
| EP1539153A4This record | European Patent Office (EPO) | A4 | |
| US2008200453A1 | United States of America | A1 | |
| AU2008233222A1 | Australia | A1 | |
| CA2693254A1 | Canada | A1 | |
| WO2008121258A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US2008293735A1 | United States of America | A1 | |
| CA2688035A1 | Canada | A1 | |
| WO2008150480A1 | World Intellectual Property Organization (WIPO) | A1 | |
| MX2009012919A | Mexico | A | |
| EP2162003A1 | European Patent Office (EPO) | A1 | |
| US7685073B2 | United States of America | B2 | |
| WO2008121258A8 | World Intellectual Property Organization (WIPO) | A8 | |
| WO2008121258A8 | World Intellectual Property Organization (WIPO) | A8 | |
| KR20100039292A | Republic of Korea | A | |
| EP2175853A1 | European Patent Office (EPO) | A1 | |
| IL202269A0 | Israel | A0 | |
| CN101754687A | China | A | |
| EP2162003A4 | European Patent Office (EPO) | A4 | |
| ZA200908299B | South Africa | B | |
| JP2010529022A | Japan | A | |
| EP2175853A4 | European Patent Office (EPO) | A4 | |
| CO6251212A2 | Colombia | A2 | |
| RU2009148809A | Russian Federation | A | |
| RU2010106647A | Russian Federation | A | |
| RU2467743C2 | Russian Federation | C2 | |
| RU2473344C2 | Russian Federation | C2 | |
| AU2008233222B2 | Australia | B2 | |
| AU2013263800A1 | Australia | A1 | |
| JP2014077022A | Japan | A | |
| RU2012154337A | Russian Federation | A | |
| JP5595268B2 | Japan | B2 | |
| AU2013263800B2 | Australia | B2 | |
| EP3090745A1 | European Patent Office (EPO) | A1 | |
| US9655865B2 | United States of America | B2 | |
| RU2624232C2 | Russian Federation | C2 | |
| US2017209539A1 | United States of America | A1 | |
| CA2693254C | Canada | C | |
| US2018177874A1 | United States of America | A1 | |
| BRPI0810954A2 | Brazil | A2 |
13 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Application deemed to be withdrawnWithdrawn18D | 18D | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWNSTAA | STAA | |
| Supplementary search report drawn up and despatchedA4 | A4 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Request for extension of the european patent (deleted)DAX | DAX | |
| Request for examination filed17P | 17P | |
| Designated contracting statesAK | AK | |
| Request for extension of the european patentAX | AX | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI |
Numbers
- Publication
- 1539153
- Application
- 37720240
Titles3
- German
- THERAPEUTISCHE BEHANDLUNG DES METABOLISCHEN SYNDROMS UND FÜR DIABETES TYP 2
- English
- THERAPEUTIC TREATMENT FOR THE METABOLIC SYNDROME AND TYPE 2 DIABETES
- French
- TRAITEMENT THERAPEUTIQUE POUR LE SYNDROME METABOLIQUE ET LES DIABETES DE TYPE 2
Classification
- CPC, 4
- A61K45/06
- A61K31/00
- A61P3/00
- A61P3/10
- IPC, 6
- A61K31 44
- A61K31 00
- A61K31 495
- A61K45 06
- A61P3 00
- A61P3 10
Designated states27
- Contracting states, 27
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Romania
- Sweden
and 3 moreShow fewer
- Slovenia
- Slovakia
- Türkiye